Skip to entry

Liraglutide and the daily GLP-1 schedule

GLP1Meds.org editorial team · Published November 18, 2026 · Last reviewed November 18, 2026

Liraglutide is the oldest of the three molecules in this reference, and it is easy to misread because it is injected every day rather than once a week. NIDDK lists Saxenda as the weight-management brand and notes that a lower dose, under the name Victoza, is approved for type 2 diabetes. This entry is about Saxenda’s weight-management label as printed in the 2026 prescribing information. It does not convert Saxenda milligrams into Wegovy or Zepbound milligrams. There is no labeled conversion. Someone comparing the daily routine with the weekly one can also read the first twelve weeks, which is a patient note about escalation in general, not a Saxenda calendar.

Who the indication names

Saxenda is indicated with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The pediatric clause includes a weight floor, greater than 60 kg, that weekly-product discussions often omit. Limitations of use say Saxenda contains liraglutide and that coadministration with other liraglutide-containing products or any other GLP-1 receptor agonist is not recommended. The label states that safety and effectiveness in pediatric patients with type 2 diabetes have not been established.

That population language is narrower and older in style than a sentence that only says “GLP-1 for weight.” An adult with overweight and no weight-related condition is outside the indication as written. An adolescent under 60 kg is outside it even if a BMI percentile is high. Those boundaries are the prescriber’s to apply. They are quoted here so a daily pen is not assumed to have Wegovy’s pediatric rule, which is framed differently.

The daily escalation

Inject Saxenda subcutaneously once daily, at any time of day, without regard to meals, in the abdomen, thigh, or upper arm. The recommended dose is 3 mg daily. Lower doses are for titration. Adults who cannot tolerate 3 mg should stop the drug, according to the label. That is different from Zepbound, where a lower maintenance dose can be an endpoint, and different from Wegovy injection, where 1.7 mg can be a maintenance dose.

Week Daily dose
1 0.6 mg
2 1.2 mg
3 1.8 mg
4 2.4 mg
5 and onward 3 mg

If a patient does not tolerate an increase, the label says to consider delaying escalation for about one additional week. Pediatric escalation can take up to 8 weeks. If a pediatric patient does not tolerate an increased dose, the dose may be lowered to the previous level. Pediatric patients who do not tolerate 3 mg daily may have the dose reduced to 2.4 mg daily. That pediatric flexibility is not the adult rule. Adult patients with type 2 diabetes should have blood glucose monitored before and during treatment.

If a dose is missed, resume the once-daily regimen at the next scheduled dose. Do not take an extra dose or increase the next one to compensate. If more than three days have passed since the last dose, reinitiate at 0.6 mg daily to reduce gastrointestinal symptoms. A person who packed the pen in a checked bag and restarted at 3 mg four days later is outside that instruction.

The 16-week adult assessment

The Saxenda label tells prescribers to evaluate change in body weight 16 weeks after initiation and to discontinue Saxenda if the patient has not lost at least 4 percent of baseline body weight, because it is unlikely the patient will achieve and sustain clinically meaningful weight loss with continued treatment. This is a labeled stopping rule. It is not a moral judgment, and it is not a rule this entry copies onto semaglutide or tirzepatide. STEP 1 and SURMOUNT-1 used different durations and did not publish a “stop at 4 percent at week 16” instruction for those drugs. Applying Saxenda’s rule to a Wegovy pen, or refusing to apply it to Saxenda because another drug’s trial ran to 68 weeks, both misunderstand which document is in force.

Sixteen weeks is also long enough that the titration to 3 mg, if tolerated, has already happened. A lack of early loss on the 0.6 mg week is not yet the 16-week assessment. Gastrointestinal effects during titration are expected enough that the escalation table exists. They do not, by themselves, prove the 16-week outcome.

Boxed warning and the warnings that matter at a daily cadence

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures. Whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans is unknown. Saxenda is contraindicated with a personal or family history of medullary thyroid carcinoma and in patients with MEN 2. Counsel patients on symptoms: a neck mass, dysphagia, dyspnea, persistent hoarseness. The label says routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.

Other warnings follow the class pattern seen with the weekly drugs: pancreatitis, gallbladder disease, severe gastrointestinal adverse reactions, risk of hypoglycemia with insulin or an insulin secretagogue, acute kidney injury in the setting of volume depletion, hypersensitivity, increased heart rate, and pulmonary aspiration during general anesthesia or deep sedation. A daily injection does not make those warnings smaller. It does mean a missed weekend is handled under the three-day restart rule above, rather than under Wegovy’s two-day weekly rule. People who travel need a plan for refrigeration as the product’s storage section describes it. This entry does not reprint a temperature range it did not recheck against the carton instruction in front of the reader. Use the medication guide dispensed with the pen.

Pregnancy language has moved over successive label revisions. Do not rely on an old wallet card that listed pregnancy as a contraindication heading if the current section places the risk in warnings. Read section 8 of the current label with the prescriber, and do not start or continue Saxenda in pregnancy on the strength of this summary.

How the average loss compares, without a fake ranking

Published summaries of the SCALE program have reported mean weight loss on the order of 8 percent with liraglutide 3 mg versus about 2.6 percent with placebo at 56 weeks, in a trial that also used a lifestyle intervention. This entry does not hang a clinical decision on that secondary retelling. The primary practical comparisons a reader can verify here are the ones with full citations already used across this reference: STEP 1’s −14.9 percent versus −2.4 percent at 68 weeks with semaglutide 2.4 mg, and SURMOUNT-1’s −15.0 to −20.9 percent at 72 weeks with tirzepatide. Those trials are not head-to-head against Saxenda. Different molecules, different eras, different visit schedules. NIDDK lists all three as options and does not publish a winner. A clinician might still choose Saxenda because of daily timing, prior response, availability, or a labeled pediatric situation the weekly drug does not match. A clinician might choose against it because the person cannot tolerate 3 mg or because a weekly product fits the indication better. Both choices can be label-consistent. Neither one is a conclusion from a single percentage.

The class map keeps Victoza and Saxenda from being treated as the same prescription. The oral and compounded entry is the place for products that are not Saxenda at all, including compounded liquids sold as if a daily GLP-1 were a commodity. Saxenda’s value, when it is the right drug, is that the dose, the 16-week check, and the restart rule are written down. A vial without those instructions is not a generic Saxenda.

Label and trial list

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
  2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  3. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. https://pubmed.ncbi.nlm.nih.gov/33567185/
  5. https://pubmed.ncbi.nlm.nih.gov/35658024/
  6. https://glp1journey.org/notes/first-twelve-weeks